Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05556642 · ClinicalTrials.gov registry record

Relapsed and Refractory Hepatoblastoma: A Prospective Registry and Liver Tumor Research Consortium Initiative

A clinical trial of Relapsed Hepatoblastoma and Refractory Hepatoblastoma, sponsored by Children's Hospital Medical Center, Cincinnati.

Recruiting
Registry status
500
Enrollment target
1
Study location

NCT05556642 is a study of Relapsed Hepatoblastoma and Refractory Hepatoblastoma that is actively recruiting participants, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 500 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05556642, a study of Relapsed Hepatoblastoma and Refractory Hepatoblastoma, is actively recruiting participants, sponsored by Children's Hospital Medical Center, Cincinnati.

RECRUITING
Registry status
500 participants
Enrollment target
1
Study location

Study Summary

There are limited data regarding the biology and treatment of relapsed/refractory hepatoblastoma (rrHBL). This project provides the infrastructure for acquisition of biological specimens, imaging, and correlative clinical data to facilitate biology studies and characterization of rrHBL. This registry will collect clinical, demographic, and pathological data, specimens (as available) and imaging from patients with rrHBL, prospectively. Cases are identified through: 1. Existing clinical and/or cancer registry databases 2. Referrals from clinicians, surgeons, or pathologists 3. Families initiating contact with Registry staff directly

Interventions

  • OTHER Biospecimen collection

Study Locations (1)

Ohio

  • Cincinnati Children's Hospital Medical Center - Cincinnati

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2022-09-07
Est. Completion 2040-09-01

What the Registry Record Tells You About NCT05556642

The ClinicalTrials.gov registry entry for NCT05556642 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital Medical Center, Cincinnati, which has 571 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Relapsed Hepatoblastoma appearing as the primary indexed condition, and to 1 intervention - of which Biospecimen collection is the first listed.

NCT05556642 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT05556642 about?

NCT05556642 is a clinical study titled "Relapsed and Refractory Hepatoblastoma: A Prospective Registry and Liver Tumor Research Consortium Initiative". There are limited data regarding the biology and treatment of relapsed/refractory hepatoblastoma (rrHBL). This project provides the infrastructure for acquisition of biological specimens, imaging, and correlative clinical data to facilitate biology studies and characterization of rrHBL. This registr...

What is the current status of trial NCT05556642?

This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2022-09-07. Estimated completion is 2040-09-01.

What conditions does trial NCT05556642 study?

This clinical trial studies the following conditions: Relapsed Hepatoblastoma, Refractory Hepatoblastoma.

What interventions are being tested in trial NCT05556642?

The interventions under investigation include: Biospecimen collection (OTHER).

Who is sponsoring clinical trial NCT05556642?

This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05556642 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.